- Home
- SHPH
as 03-28-2025 4:00pm EST
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | GAITHERSBURG |
| Market Cap: | 2.2M | IPO Year: | 2022 |
| Target Price: | N/A | AVG Volume (30 days): | 262.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.30 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.33 - $4.71 | Next Earning Date: | 05-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Shuttle Pharmaceuticals Holdings Inc. News
SHPH Breaking Stock News: Dive into SHPH Ticker-Specific Updates for Smart Investing
GlobeNewswire
17 days ago
Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering
GlobeNewswire
19 days ago
Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering
GlobeNewswire
19 days ago
Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities
GlobeNewswire
a month ago
Shuttle Pharma Provides Corporate Update and Reports 2024 Results
GlobeNewswire
2 months ago
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
GlobeNewswire
3 months ago
Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
GlobeNewswire
3 months ago
Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
GlobeNewswire
4 months ago
Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient
Compare SHPH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SHPH Shuttle Pharmaceuticals Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.